Open Access
Article
SUMO conjugation and cardiovascular development
Jun Wang1
1
Institute of Biosciences and Technology, Texas AandM Health Science Center, 2121 W. Holcombe, Boulevard, Houston, TX 77030, USA. junwang@ibt.tamhsc.edu
DOI: 10.2741/3304 Volume 14 Issue 4, pp.1219-1229
Published: 01 January 2009
(This article belongs to the Special Issue Advances in systemic inflammatory response)
Abstract

SUMOs (Small Ubiquitin-like modifiers) belong to a superfamily of ubiquitin like proteins (Ubls) that are covalently conjugated to their substrates via enzymatic cascade reactions. The heterodimeric activating complex (SAE1/SAE2, E1) and conjugating enzyme (Ubc9, E2) required for the SUMO conjugation pathway are distinct from those involved in other Ubl pathways, and the presence of ligases (E3) stimulates the conjugation reaction. SUMO is implicated in a variety of physiological as well as pathological processes such as cell division, signal transduction, DNA damage and repair, and cancer development. This review focuses on the fundamental features of SUMO conjugation and its potential implication in cardiovascular development.

Share and Cite
Jun Wang. SUMO conjugation and cardiovascular development. Frontiers in Bioscience-Landmark. 2009. 14(4); 1219-1229.